机构:[1]Department of Oncology, Beijing Biohealthcare Biotechnology Co. Ltd[2]Department of Oncology, Beijing Tongren Hospital, Capital Medical University首都医科大学附属北京同仁医院临床科室肿瘤中心[3]Department of Interventional Therapy Center, Beijing Shunyi District Hospital, Beijing, China
The paradoxical coexistence of spontaneous tumor antigen-specific immune response with progressive disease in cancer patients need to dissect the molecular pathways involved in tumor induced T-cell dysfunction or exhaustion. Programmed cell death 1 (PD-1) has been identified as a marker of exhausted T cells in chronic disease states, and blockade of PD-1-PD-L1 interactions has been shown to partially restore T-cell function. We have found that T-cell immunoglobulin mucin (Tim) 3 is expressed on CD8(+) tumor-infiltrating lymphocytes (TILs) isolated from patients with colorectal cancer. All T-cell immunoglobulin mucin 3 (Tim-3(+)) TILs coexpress PD-1, and Tim-3(+) PD-1(+) CD8(+) TILs represent the predominant fraction of Tcells infiltrating tumors. Tim-3(+) PD-1(+) CD8(+) TILs exhibit the most severe exhausted phenotype as defined by failure to produce cytokines, such as interferon-gamma, tumor necrosis factor-alpha, and interleukin-2. We further find that combined targeting of the Tim-3 and PD-1 pathways increased the frequencies of not only interferon-gamma and tumor necrosis factor-alpha but also frequencies of proliferating tumor antigen-specific CD8(+) T cells than targeting either pathway alone. A concomitant decrease in regulatory T cells and enhanced killing in a cytotoxicity assay was observed. Collectively, our findings support the use of Tim-3-Tim-3L blockade together with PD-1-PD-L1 blockade to reverse tumor-induced T-cell exhaustion/dysfunction in patients with colorectal cancer.
基金:
Beijing Science and Technology [Z14010101101]
基金编号:Z14010101101
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类|2 区医学
小类|3 区免疫学3 区医学:研究与实验3 区肿瘤学
最新[2025]版:
大类|4 区医学
小类|4 区免疫学4 区医学:研究与实验4 区肿瘤学
JCR分区:
出版当年[2014]版:
Q1MEDICINE, RESEARCH & EXPERIMENTALQ2IMMUNOLOGYQ2ONCOLOGY
最新[2023]版:
Q2MEDICINE, RESEARCH & EXPERIMENTALQ2ONCOLOGYQ3IMMUNOLOGY
第一作者机构:[1]Department of Oncology, Beijing Biohealthcare Biotechnology Co. Ltd
通讯作者:
通讯机构:[1]Department of Oncology, Beijing Biohealthcare Biotechnology Co. Ltd[*1]Center for Cancer Research, FL2, Building 3, Park B, Shunyi District Airport High Tech Zoon, Beijing 101300, China
推荐引用方式(GB/T 7714):
Liu Jingwei,Zhang Shurong,Hu Yuefeng,et al.Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines[J].JOURNAL OF IMMUNOTHERAPY.2016,39(4):171-180.doi:10.1097/CJI.0000000000000122.
APA:
Liu, Jingwei,Zhang, Shurong,Hu, Yuefeng,Yang, Zhaomin,Li, Jingpo...&Lu, Xu.(2016).Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.JOURNAL OF IMMUNOTHERAPY,39,(4)
MLA:
Liu, Jingwei,et al."Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines".JOURNAL OF IMMUNOTHERAPY 39..4(2016):171-180